Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis

Journal of Inflammation Research

Volumn 6, Issue 1, 2013, Pages

  Bergin, David A ^a   Hurley, Killian ^a   Mehta, Adwait ^a   Cox, Stephen ^a   Ryan, Dorothy ^a   O'Neill, Shane J ^a   Reeves, Emer P ^a   McElvaney, Noel G ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Bronchiectasis; Cystic fibrosis; Inflammation; Proteases

Indexed keywords

GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 8; LEUKOCYTE ELASTASE;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE RELEASE; DISEASE MARKER; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG LAVAGE; MALE; NON CYSTIC FIBROSIS BRONCHIECTASIS; SAMPLE;

EID: 84873146970     PISSN: None     EISSN: 11787031     Source Type: Journal    
DOI: 10.2147/JIR.S40081     Document Type: Article

References (75)

1. Bilton D. Update on non-cystic fibrosis bronchiectasis. Curr Opin Pulm Med. 2008;14(6):595-599.
2. Seitz AE, Olivier KN, Adjemian J, Holland SM, Prevots DR. Trends in bronchiectasis among Medicare beneficiaries in the United States, 2000-2007. Chest. 2012;142(2):432-439.
3. Keistinen T, Saynajakangas O, Tuuponen T, Kivela SL. Bronchiectasis: an orphan disease with a poorly understood prognosis. Eur Respir J. 1997;10(12):2784-2787.
4. Swinson DR, Symmons D, Suresh U, Jones M, Booth J. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol. 1997;36(6):689-691.
5. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, et al. Factors associated with bronchiectasis in patients with COPD. Chest. 2011;140(5):1130-1137.
6. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55(8):635-642.
7. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(4):400-407.
8. Boucher RC, Stutts MJ, Knowles MR, Cantley L, Gatzy JT. Na+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest. 1986;78(5):1245-1252.
9. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science. 1995;269(5225):847-850.
10. Fajac I, Viel M, Sublemontier S, Hubert D, Bienvenu T. Could a defective epithelial sodium channel lead to bronchiectasis? Respir Res. 2008;9:46.
11. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756.
12. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman-Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132(5):1565-1572.
13. Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic fibrosis. Expert Opin Ther Targets. 2008;12(2):145-157.
14. Tsang KW, Chan K, Ho P, et al. Sputum elastase in steady-state bronchiectasis. Chest. 2000;117(2):420-426.
15. Muhlebach MS, Noah TL. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med. 2002;165(7):911-915.
16. Reeves EP, Williamson M, Byrne B, et al. IL-8 dictates glycosaminoglycan binding and stability of IL-18in cystic fibrosis. J Immunol. 2010;184(3):1642-1652.
17. Guran T, Ersu R, Karadag B, et al. Association between inflammatory markers in induced sputum and clinical characteristics in children with non-cystic fibrosis bronchiectasis. Pediatr Pulmonol. 2007;42(4):362-369.
18. O'Connor CM, FitzGerald MX. Matrix metalloproteases and lung disease. Thorax. 1994;49(6):602-609.
19. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996;149(1):273-282.
20. Jackson PL, Xu X, Wilson L, et al. Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: Implications to cystic fibrosis proteolytic dysfunction. Mol Med. 2010;16(5-6):159-166.
21. Sepper R, Konttinen YT, Ding Y, Takagi M, Sorsa T. Human neutrophil collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease. Chest. 1995;107(6):1641-1647.
22. Sepper R, Konttinen YT, Sorsa T, Koski H. Gelatinolytic and type IV collagenolytic activity in bronchiectasis. Chest. 1994;106(4):1129-1133.
23. Gaggar A, Li Y, Weathington N, et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol. 2007;293(1):L96-L104.
24. Ratjen F, Hartog CM, Paul K, Wermelt J, Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax. 2002;57(11):930-934.
25. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A. 1990;87(23):9188-9192.
26. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med. 1994;331(10):637-642.
27. Ramsey BW, Astley SJ, Aitken ML, et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis. 1993;148(1):145-151.
28. Ranasinha C, Assoufi B, Shak S, et al. Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. Lancet. 1993;342(8865):199-202.
29. Kristensen K. Recombinant human DNase in conditions other than cystic fibrosis. Ugeskr Laeger. 2010;172(8):616-619.
30. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest. 1998;113(5):1329-1334.
31. Naidich DP, McCauley DI, Khouri NF, Stitik FP, Siegelman SS. Computed tomography of bronchiectasis. J Comput Assist Tomogr. 1982;6(3):437-444.
32. Ooi CY, Dupuis A, Ellis L, et al. Comparing the American and European diagnostic guidelines for cystic fibrosis: same disease, different language? Thorax. 2012;67(7):618-624.
33. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65 Suppl 1:i1-i58.
34. Bergsson G, Reeves EP, McNally P, et al. LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline. J Immunol. 2009;183(1):543-551.
35. Bergin DA, Greene CM, Sterchi EE, et al. Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. J Biol Chem. 2008;283(46):31736-31744.
36. Montano M, Beccerril C, Ruiz V, Ramos C, Sansores RH, Gonzalez-Avila G. Matrix metalloproteinases activity in COPD associated with wood smoke. Chest. 2004;125(2):466-472.
37. Geraghty P, Rogan MP, Greene CM, et al. Alpha-1-antitrypsin aerosolised augmentation abrogates neutrophil elastase-induced expression of cathepsin B and matrix metalloprotease 2in vivo and in vitro. Thorax. 2008;63(7):621-626.
38. Geraghty P, Rogan MP, Greene CM, et al. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J Immunol. 2007;178(9):5871-5878.
39. Devaney JM, Greene CM, Taggart CC, Carroll TP, O'Neill SJ, McElvaney NG. Neutrophil elastase up-regulates interleukin-8 via toll-like receptor 4. FEBS Lett. 2003;544(1-3):129-132.
40. Walsh DE, Greene CM, Carroll TP, et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6in human bronchial epithelium. J Biol Chem. 2001;276(38):35494-35499.
41. Greene CM, Meachery G, Taggart CC, et al. Role of IL-18in CD4+ T lymphocyte activation in sarcoidosis. J Immunol. 2000;165(8):4718-4724.
42. Armstrong DS, Hook SM, Jamsen KM, et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol. 2005;40(6):500-510.
43. Hartl D, Griese M, Kappler M, et al. Pulmonary T(H)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol. 2006;117(1):204-211.
44. Downey DG, Martin SL, Dempster M, et al. The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol. 2007;42(3):216-220.
45. Eagan TM, Gabazza EC, C DA-G, et al. TNF-alpha is associated with loss of lean body mass only in already cachectic COPD patients. Respir Res. 2012;18:13:48.
46. Levy H, Kalish LA, Huntington I, et al. Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol. 2007;42(3):256-262.
47. Long H, Luo H, Chen P, Li Y. Correlation among the levels of C-reactive protein and interleukin-18, quality of life, and lung function in patients with chronic obstructive pulmonary disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011;36(11):1090-1096.
48. Tsang KW, Rutman A, Tanaka E, et al. Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitro. Eur Respir J. 1994;7(10):1746-1753.
49. Grimwood K. Airway microbiology and host defences in paediatric non-CF bronchiectasis. Paediatr Respir Rev. 2011;12(2):111-118.
50. Chotirmall SH, Branagan P, Gunaratnam C, McElvaney NG. Aspergillus/allergic bronchopulmonary aspergillosis in an Irish cystic fibrosis population: a diagnostically challenging entity. Respir Care. 2008;53(8):1035-1041.
51. Guyot N, Bergsson G, Butler MW, et al. Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases. Biol Chem. 2010;391(6):705-716.
52. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med. 1995;151(4):1075-1082.
53. Suter S, Schaad UB, Tegner H, Ohlsson K, Desgrandchamps D, Waldvogel FA. Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis. 1986;153(5):902-909.
54. Karakoc GB, Inal A, Yilmaz M, Altintas DU, Kendirli SG. Exhaled breath condensate MMP-9 levels in children with bronchiectasis. Pediatr Pulmonol. 2009;44(10):1010-1016.
55. Shamamian P, Schwartz JD, Pocock BJ, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol. 2001;189(2):197-206.
56. Chakrabarti S, Patel KD. Matrix metalloproteinase-2 (MMP-2) and MMP-9in pulmonary pathology. Exp Lung Res. 2005;31(6):599-621.
57. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995;152(6 Pt 1):2111-2118.
58. Hilliard TN, Regamey N, Shute JK, et al. Airway remodelling in children with cystic fibrosis. Thorax. 2007;62(12):1074-1080.
59. Solic N, Wilson J, Wilson SJ, Shute JK. Endothelial activation and increased heparan sulfate expression in cystic fibrosis. Am J Respir Crit Care Med. 2005;172(7):892-898.
60. Khatri IA, Bhaskar KR, Lamont JT, Sajjan SU, Ho CK, Forstner J. Effect of chondroitinase ABC on purulent sputum from cystic fibrosis and other patients. Pediatr Res. 2003;53(4):619-627.
61. Rahmoune H, Lamblin G, Lafitte JJ, Galabert C, Filliat M, Roussel P. Chondroitin sulfate in sputum from patients with cystic fibrosis and chronic bronchitis. Am J Respir Cell Mol Biol. 1991;5(4):315-320.
62. Frevert CW, Kinsella MG, Vathanaprida C, et al. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. Am J Respir Cell Mol Biol. 2003;28(4):464-472.
63. Reeves EP, Williamson M, O'Neill SJ, Greally P, McElvaney NG. Nebulised hypertonic saline decreases interleukin-8in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 2011;183(11):1517-1523.
64. Chan ED, Choi HS, Cool C, Accurso FJ, Fantuzzi G. Interleukin-18 expression in cystic fibrosis lungs. Chest. 2002;121(Suppl 3):84S-85S.
65. Hauber HP, Beyer IS, Meyer A, Pforte A. Decreased interleukin-18 expression in BAL cells and peripheral blood mononuclear cells in adult cystic fibrosis patients. J Cyst Fibros. 2004;3(2):129-131.
66. Kawakami K, Koguchi Y, Qureshi MH, et al. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol Lett. 2000;186(1):121-126.
67. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet. 1991;337(8738):392-394.
68. Griese M, Latzin P, Kappler M, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J. 2007;29(2):240-250.
69. Knutsen AP, Hutchinson PS, Albers GM, Consolino J, Smick J, Kurup VP. Increased sensitivity to IL-4in cystic fibrosis patients with allergic bronchopulmonary aspergillosis. Allergy. 2004;59(1):81-87.
70. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-698.
71. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178(2):139-148.
72. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139-1147.
73. Vos R, Vanaudenaerde BM, Verleden SE, et al. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection. Transplantation. 2012;94(2):101-109.
74. Willems-Widyastuti A, Vanaudenaerde BM, Vos R, et al. Azithromycin attenuates fibroblast growth factors induced vascular endothelial growth factor via p38(MAPK) signaling in human airway smooth muscle cells. Cell Biochem Biophys. December 29, 2011. [Epub ahead of print.]
75. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):660-667.